2026

Impact of anti-T-lymphocyte globulin dosing on graft versus host disease in matched sibling peripheral blood stem cell transplantation
Massoud R, Klyuchnikov E, Heidenreich S, Manjarres M, Rudolph I, Krause R, Zeck G, Langebrake C, Dadkhah A, Sabauri R, Niederwieser C, Schäfersküpper M, Marquard F, Harfmann M, Oechsler S, Weise G, Rathje K, Gagelmann N, Lueck C, Steiner N, Wolschke C, Ayuk F, Kröger N
BONE MARROW TRANSPL. 2026 [Epub ahead of print].

2025

Clearance of Driver Mutations after Transplantation for Myelofibrosis
Gagelmann N, Quarder M, Badbaran A, Rathje K, Janson D, Lück C, Richter J, Marquard F, Oechsler S, Massoud R, Klyuchnikov E, Rudolph I, Schäfersküpper M, Niederwieser C, Heidenreich S, Berger C, Fehse B, Wolschke C, Ayuk F, Kröger N
NEW ENGL J MED. 2025;392(2):150-160.

Safety and efficacy of the ROCK-2-inhibitor Belumosudil in cGvHD treatment - a retrospective, German-Swiss multicenter real-world data analysis
Heidenreich S, Egger-Heidrich K, Halter J, Jost L, Stölzel F, Perl M, Denk A, Edinger M, Herr W, Kröger N, Wolff D, Ayuk F, Fante M
BONE MARROW TRANSPL. 2025;60(4):439-446.

Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation
Lastovytska I, Heidenreich S, Klyuchnikov E, Niederwieser C, Gagelmann N, Richter J, Massoud R, Rathje K, Perekhrestenko T, Zeck G, Lück C, Janson D, Wolschke C, Ayuk F, Kröger N
HAEMATOLOGICA. 2025;110(7):1536-1544.

Sequential versus standard conditioning in untreated MDS patients with blasts undergoing allogeneic HSCT
Massoud R, Klyuchnikov E, Steiner N, Manjarres M, Zeck G, Krause R, Heidenreich S, Langebrake C, Dadkhah A, Rudolph I, Sabauri R, Niederwieser C, Perekhrestenko T, Reichard M, Schäfersküpper M, Marquard F, Oechsler S, Weise G, Rathje K, Harfmann M, Gagelmann N, Lück C, Wolschke C, Ayuk F, Kröger N
BONE MARROW TRANSPL. 2025;60(12):1642-1648.

Sequential Conditioning With FLAMSA Does Not Improve Outcomes of Allogeneic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia Patients
Massoud R, Klyuchnikov E, Steiner N, Zeck G, Heidenreich S, Langebrake C, Niederwieser C, Rathje K, Gagelmann N, Janson D, Wolschke C, Ayuk F, Kröger N
TRANSPL CELL THER. 2025;31(1):20.e1-20.e14.

Different clearance of KITD816V mutation and tryptase levels after haematopoietic cell transplantation in patients with systemic mastocytosis with associated haematological neoplasm
Niederwieser C, Badbaran A, Massoud R, Gagelmann N, Kunte A, Klyuchnikov E, Seyedi N, Heidenreich S, Rudolph I, Zeck G, Lück C, Janson D, Wolschke C, Ayuk F, Kröger N
BRIT J HAEMATOL. 2025 [Epub ahead of print];207(2):509-14.

Clinical and Immune Effects of Peri-Transplantation JAK Inhibition for Myelofibrosis
Rathje K, Gagelmann N, Badbaran A, Langebrake C, Dadkhah A, Richter J, Massoud R, Schäfersküpper M, Marquard F, Oechsler S, Klyuchnikov E, Rudolph I, Heidenreich S, Niederwieser C, Lueck C, Janson D, Wolschke C, Fehse B, Ayuk F, Kröger N
AM J HEMATOL. 2025;100(2):200-209.

Belumosudil for Chronic Graft-Versus-Host Disease: A Systematic Review and Meta-Analysis
Rathje K, Gagelmann N, Heidenreich S, Richter J, Marquard F, Massoud R, Klyuchnikov E, Lueck C, Rudolph I, Ayuk F
TRANSPL CELL THER. 2025 [Epub ahead of print].

Comparable Results Between 8 and 12 Gray TBI in Combination With Fludarabine and Post-Transplant Cyclophosphamide in MRD-Negative but Not in MRD-Positive Acute Lymphoblastic Leukemia Patients Transplanted in First Complete Remission
Steiner N, Massoud R, Richter J, Perekhrestenko T, Gagelmann N, Niederwieser C, Rathje K, Lastovytska I, Schäfersküpper M, Heidenreich S, Rudolph I, Zeck G, Janson D, Wolschke C, Ayuk F, Klyuchnikov E, Kröger N
EUR J HAEMATOL. 2025;114(1):79-88.

2024

Successful treatment of refractory checkpoint inhibitor-induced hepatitis with quadruple therapy including extracorporeal photopheresis and infliximab
Hansen I, Kött J, Heidenreich S, Ayuk F, Doll P, Abeck F, Booken N, Gebhardt C, Schneider S
JEADV CLIN PRACT. 2024;3(1):317-320.

Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation
Oechsler S, Gagelmann N, Wolschke C, Janson D, Badbaran A, Klyuchnikov E, Massoud R, Rathje K, Richter J, Schäfersküpper M, Niederwieser C, Kunte A, Heidenreich S, Ayuk F, Kröger N
BONE MARROW TRANSPL. 2024;59(4):550-557.

Anti-T-lymphocyte globulin (ATLG) compared to post-transplant cyclophosphamide as GvHD prophylaxis in ALL patients undergoing allogeneic stem cell transplantation
Steiner N, Massoud R, Klyuchnikov E, Gagelmann N, Richter J, Niederwieser C, Rathje K, Urbanowicz T, Kunte A, Engelmann J, Ihne C, Lastovytska I, Lindhauer C, Marquard F, Reichard M, Ryzhkova A, Sabauri R, Schäfersküpper M, Seyedi N, Kalogeropoulos G, Heidenreich S, Rudolph I, Zeck G, Janson D, Wolschke C, Ayuk F, Kröger N
BONE MARROW TRANSPL. 2024;59(9):1265-1274.

Development and Validation of a Concise Objectifiable Risk Evaluation Score for Non-Relapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation
Weise G, Massoud R, Krause R, Heidenreich S, Janson D, Klyuchnikov E, Wolschke C, Zeck G, Kröger N, Ayuk F
CANCERS. 2024;16(3):.

2022

Comparison of immune reconstitution between anti-T-lymphocyte globulin and post-transplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation
Massoud R, Gagelmann N, Fritzsche-Friedland U, Zeck G, Heidenreich S, Wolschke C, Ayuk F, Christopeit M, Kröger N
HAEMATOLOGICA. 2022;107(4):857-867.

2021

Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection
Christopeit M, Reichard M, Niederwieser C, Massoud R, Klyuchnikov E, Haase N, Wolschke C, Ayuk F, Heidenreich S, Kröger N
BONE MARROW TRANSPL. 2021;56(6):1478-1481.

Viral Dynamics of SARS-CoV-2 in Critically Ill Allogeneic Hematopoietic Stem Cell Transplant Recipients and Immunocompetent Patients with COVID-19
Roedl K, Heidenreich S, Pfefferle S, Jarczak D, Urbanowicz T, Nörz D, Aepfelbacher M, Kröger N, Kluge S, Lütgehetmann M, Christopeit M, Wichmann D
AM J RESP CRIT CARE. 2021;203(2):242-245.

2020

Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis
Atagunduz I, Klyuchnikov E, Wolschke C, Janson D, Heidenreich S, Christopeit M, Ayuk F, Kröger N
CANCERS. 2020;12(11):.

2019

Unklare Panzytopenie bei einem 52-jährigen Patienten
Heidenreich S, van Randenbourgh A, Ayuk F, Kröger N, Schmiedel S, Asemissen A, Oelrich J, Wolschke C
INTERNIST. 2019;60(8):867-870.

Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia
Schetelig J, de Wreede L, van Gelder M, Koster L, Finke J, Niederwieser D, Beelen D, Mufti G, Platzbecker U, Ganser A, Heidenreich S, Maertens J, Socié G, Brecht A, Stelljes M, Kobbe G, Volin L, Nagler A, Vitek A, Luft T, Ljungman P, Yakoub-Agha I, Robin M, Kröger N
LEUKEMIA. 2019;33(3):686-695.

2017

Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection
Heidenreich S, Kröger N
FRONT IMMUNOL. 2017;8:41.

Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT
Heidenreich S, Ziagkos D, de Wreede L, van Biezen A, Finke J, Platzbecker U, Niederwieser D, Einsele H, Bethge W, Schleuning M, Beelen D, Tischer J, Nagler A, Glass B, Maertens J, Yáñez L, Beguin Y, Sill H, Scheid C, Stelljes M, Ganser A, Zachée P, Selleslag D, de Witte T, Robin M, Kröger N
BIOL BLOOD MARROW TR. 2017;23(1):44-52.

2012

Impact of the NK cell receptor LIR-1 (ILT-2/CD85j/LILRB1) on cytotoxicity against multiple myeloma.
Heidenreich S, Zu Eulenburg C, Hildebrandt Y, Stübig T, Sierich H, Badbaran A, Eiermann T, Binder T, Kröger N
Clin Dev Immunol. 2012;2012:652130.

Letzte Aktualisierung aus dem FIS: 23.02.2026 - 00:45 Uhr